Key Takeaways
- Guidance raised across the board: Consolidated FY27 revenue growth lifted from 12–13% to 14–16%, and EBITDA margin guidance raised from ~22% to ~23%, driven by generic upside, strong India, and API growth.
- Institutional business flattered the quarter: ~107% growth came from ~₹40 cr of nominated shipments that slipped from March into April; management is explicit that shipment timing is not in its control.
- Unichem is the swing factor: U.S. grew 27%, Brazil 52%, API ~73%, but management declined to revise Unichem's 10% growth / 13% EBITDA margin guidance, saying it wants more quarters of evidence.
- Margin expansion is operating leverage, not material savings: Personnel and manufacturing costs to sales fell ~1.4% and ~0.9% respectively; material cost savings contributed only 0.14%.
- What to watch next quarter: Whether Unichem's momentum sustains enough to justify a guidance revision, whether institutional shipments normalize, and how freight cost increases hitting July–August affect margins.
Guidance Revision & The Unichem Question
- Revenue guidance raised to 14–16% for FY27, up from 12–13%, on generic business upside, strong India performance, and good API growth.
- EBITDA margin guidance raised to ~23% from ~22%, with freight rate increases already factored in.
- India guidance intact: 12–13% growth for FY27 remains unchanged, with volume growth at ~5%, higher than industry.
- Institutional business guided down to reality: Single-digit growth expected, overall range ₹260–300 cr; management is "not looking for very high growth" after this quarter's spillover.
- Unichem guidance deliberately left alone: 10% growth and 13% EBITDA margin stands, but management framed it as a wait-and-watch rather than a confirmation.
A.K. Jain: "Unichem guidelines, I'm not revising right now. Let's see for some more quarters how it performs and we are working hard to deliver more growth, but let us see on ground and thereafter, we'll revise the guidelines."
Unichem: The Integration Payoff
- U.S. growth of 27% was driven by Ipca portfolio sold through Unichem growing ~37%, while Unichem's own portfolio grew only ~9%.
- Brazil turned a corner: Grew ~52%, and management noted Brazil is now positive after losses, contributing to Unichem margin improvement.
- API business inflected: Unichem API moved from ₹33–34 cr to ~₹58 cr, a ~73% improvement.
- Margin drivers are structural: Own captive API cost reductions, a strong European business, and Brazil turning positive; Ipca API supply to Unichem remains negligible at one product order.
- The next leg waits on approvals: Europe, Australia, NZ, Canada, and Chile approvals take ~1.5 years from filing; once they arrive, Unichem's margin profile changes because the current mix is U.S.-heavy where margins are under pressure.
- U.S. growth outlook: Management sees ~15–17% growth as possible on the current portfolio, with combined Ipca-Unichem launches of ~7–8 products per year.
A.K. Jain: "Maybe around 15%, 16%, 17% kind of growth is possible, but currently looking at portfolio and other things."
Margin Walk & Cost Structure
- Consolidated EBITDA improved ~4.49% driven mainly by operating leverage: personnel cost to sales down ~1.5%, manufacturing and other cost down ~1.19%, material cost down ~1.35%.
- Standalone EBITDA improved ~2.4% with personnel cost to sales down ~1.41% and manufacturing cost down ~0.91%; material cost savings contributed only 0.14%.
- Material costs are volatile: They rose 21% in line with 21% turnover growth this quarter, after being down ~2% last year; petroleum prices and supply chain disturbances drove the swings.
- Rupee depreciation helped but cut both ways: ~5% of the 21% growth came from rupee depreciation; it helped margins but material costs also moved up since ~25% of costs are dollar-linked.
- Freight is the near-term pressure: Shipment delays, container nonavailability, and significant logistic cost increases are rising further from July to August; South America destinations are particularly difficult.
- Interest burden nearly gone: All ~USD 50 mn dollar loans were fully repaid before March, ahead of dollar depreciation; debt is now ~₹193 cr long-term only with zero working capital debt.
A.K. Jain: "In fact, before these dollar depreciation started, we have almost every dollar loan prepaid every dollar loan. We don't have those kind of debt in books."
India Business & Field Force
- Chronic segment outperformed: 17.2% growth vs IPM ~15.2%, while acute grew 8.9% vs IPM 4.5%.
- Antimalarial dragged acute: Declined ~24% this quarter, but malaria is now only ~1% of business, limiting the damage.
- Field force expansion complete: ~7,000 reps in place, with ~200 more to be added mid-year for new divisions; no significant increase beyond that.
- Price environment is favorable: Management sees no renegotiations where prices are reduced; prices are increasing everywhere as costs move up.
A.K. Jain: "I think there are no such renegotiations of the prices where the prices are to be reduced, no. Rather we are increasing the prices everywhere because your costs are also moving up."
Biotech: The Long-Dated Option
- Two products in engineering batches with results in line with expectations; validations ongoing.
- Phase III waivers received from European and U.S. authorities for biosimilars, and clinical trial protocols already consulted with European, U.K., and U.S. authorities.
- Revenue timeline is FY29–FY30: Validations and stability charging this year, initial stability results mid-next year, clinical work starts next financial year.
- Yield advantage is the thesis: Known titer values are practically double or more of current market levels, which management flagged as a key differentiator.
- Portfolio is mostly patent-expired products with one large product targeted around patent expiry; management did not name products or therapeutic areas when pressed.
- Capacity expansion likely needed in 1–2 years as the pipeline advances.
A.K. Jain: "Most of the products are -- known titer values are practically double or more of the current known in the market side."
Lyka Labs & Other Portfolio Items
- Lyka revenue has not grown and EBITDA is negative: The B2B supply business is declining while own promoted businesses in animal health, critical care, and IVF are building up; some divisions are at breakeven, some below.
- Field force costs are the Lyka drag: Significant additions over the last two years are driving costs while revenue lags.
- Management stance is hopeful but unquantified: Lyka is "on the right path" with no specific turnaround timeline given.
- Europe generic business is the standout: Grew from ₹33 cr to ₹137 cr (~70%), driven by new product launches; both Europe and U.K. performed very well, with Unichem portfolio not yet contributing.
- Acacia ROW business almost doubled from ₹8 cr to ₹17 cr.
- Capex of ₹700–800 cr planned this year across capacity expansion, biotech, and API plants at Dewas, Wardha, and Pithampur.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated revenue growth | 14–16% for FY27, raised from 12–13% | FY27 |
| Consolidated EBITDA margin | ~23%, raised from ~22% | FY27 |
| India business growth | 12–13% | FY27 |
| Institutional business | ₹260–300 cr, single-digit growth | FY27 |
| Unichem growth and EBITDA margin | 10% growth, 13% EBITDA margin, unchanged | FY27, under review |
| U.S. growth | ~15–17% possible on current portfolio | FY27 |
| U.S. launches | ~7–8 combined Ipca-Unichem per year | Annual run-rate |
| Capex | ₹700–800 cr | FY27 |
| Term loan repayment | ~₹70 cr year-end balance repaid | FY28 |
| Medium-term standalone margin | ~26% to ~30% | 2–3 years |
| Medium-term consolidated margin | ~25% | 2–3 years |
| Biotech revenue start | FY29–FY30 | FY29–FY30 |
| Biotech clinical trials start | Next financial year | FY28 |
| FY28 guidance | To be given at Q4 | Q4 FY27 |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Consolidated revenue | ₹2,788 cr, +21% YoY from ₹2,309 cr |
| Consolidated EBITDA margin | 22.88%, up from 18.39% YoY, an improvement of ~4.49 ppt |
| Consolidated EBITDA | ₹638 cr, +50% YoY from ₹425 cr |
| Standalone EBITDA margin | 26%, up from 23.82% YoY |
| Standalone EBITDA | ₹557 cr, +34% YoY from ₹416 cr |
| Domestic formulation revenue | ₹1,082 cr, +13% YoY from ₹961 cr |
| Export revenue | ₹603 cr, +34% YoY from ₹450 cr |
| API revenue | ₹424 cr, +30% YoY from ₹362 cr |
| FY27 revenue growth guidance | 14% to 16%, revised upward from 12% to 13% |
| FY27 consolidated EBITDA margin guidance | ~23%, revised upward from ~22% |
| Domestic formulation volume growth | ~5% |
| Domestic formulation price growth | ~4.5% to 5% |
| Domestic formulation new product launch contribution | ~2% |
| IQVIA market share | ~2.08%, up from 2.07% in March 2026 |
| Chronic segment growth | ~17.2%, vs IPM chronic growth of ~15.2% |
| Acute segment growth | ~8.9%, vs IPM growth of 4.5% |
| Institutional generic revenue | ₹111.75 cr, +107% YoY from ₹58 cr; includes ~₹40 cr of March shipment shifted to April |
| Generic business excluding tender | ₹340 cr, +27% YoY from ₹268 cr |
| Promotional branded ROW revenue | ₹143 cr, +16% YoY from ₹124 cr |
| EU business revenue | ₹137 cr, up from ₹33 cr YoY |
| U.S. shipments growth | ~8% YoY |
| Unichem U.S. business growth | ~27% YoY |
| Unichem Brazil growth | ~52% YoY |
| Unichem API revenue | ~₹58 cr, +73% YoY from ₹33–34 cr |
| Acacia (ROW) revenue | ₹17 cr, nearly double from ₹8 cr YoY |
| Material cost to sales | ~25% of sales; savings contributed only 0.14% to EBITDA margin improvement |
| Personnel cost to sales change | -1.41% YoY |
| Manufacturing cost to sales change | -0.91% YoY |
| Rupee depreciation contribution to revenue growth | 5% of the 21% overall growth; dollar up ~11% YoY |
| India field force | ~7,000 medical reps; plan to add ~200 mid-year |
| Capex guidance FY27 | ₹700–800 cr |
| Long-term debt | ₹193 cr; zero working capital debt; year-end term loan balance expected ~₹70 cr |
| Biotech pipeline | 7 candidates; 2 in engineering batches; ~₹100 cr additional biotech investment this year |
| U.S. launches per year (Ipca + Unichem) | 7 to 8 combined; 3–4 each |
| U.S. growth expectation | ~15% to 17% possible |
| Standalone EBITDA margin long-term potential | ~30%, up from current ~26% |
| Consolidated EBITDA margin in 2–3 years | ~25% |